Haleos Labs share price & results
- Jun 2026
- Sept 2026
Hyderabad-based manufacturer of Pharmaceutical APIs and intermediates (formerly SMS Lifesciences), serving generic and innovator customers globally from USFDA/PMDA/WHO-GMP accredited plants.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 67.8 | −14.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 14.2 | +0.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 3.2 | −37.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 7.69 | −2.4 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -6.29 | −11.8 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -3.12 | −15.9 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance +31.3% 1Y
1Y: ₹1,122.4 on 24 Oct 2025 → ₹1,474. High ₹1,700 (11 May 2026), low ₹1,119.6 (27 Oct 2025).
- Previous close
- ₹1,463.7
- Market cap
- ₹438 Cr
- 52-week range
- ₹1,119.6 – ₹1,700
- One year
- +31.65%
- Price to earnings (TTM to Jun 2026)
- 27.70×
- Return on equity (TTM to Jun 2026)
- 7.69%
Overview
- Symbol
- NSE:HALEOSLABS
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What HALEOS LABS LIMITED does
Based on the company's own presentations, annual report and earnings calls.
The company manufactures Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates for generic and innovator drug makers worldwide, operating since 1990 from a corporate office and manufacturing/research facilities in Hyderabad. Its majority-owned subsidiary, Mahi Drugs Private Limited, runs a separate API-intermediates plant at Parawada, Visakhapatnam. Products are exported to customers across markets including China, Indonesia, USA, Malaysia, Singapore, Spain and Brazil. The company was renamed from SMS Lifesciences India Limited to Haleos Labs Limited in 2025, with its underlying API/intermediates business unchanged.
Segments
- APIs & Intermediates (standalone)
- Intermediates of APIs (Mahi Drugs subsidiary)
- Manufacturing facilities
- 2 API/intermediates plants — Unit 1 (Kazipally, Hyderabad, Telangana) and Mahi Drugs plant (Parawada, Visakhapatnam, Andhra Pradesh)
- Unit 1 plant footprint
- Plant area 47,581.62 Sq.M; built-up area 13,619.87 Sq.M; green belt 15,248 Sq.M
- Mahi Drugs production lines
- 2 API lines & 4 intermediate blocks (213 KL); batch sizes 500 g to 1,000 kg
- R&D facility
- DSIR-approved R&D centre at Sanath Nagar, Hyderabad, staffed by a 70-member team
- DMFs filed (FY25)
- 7 (across SMS Lifesciences & Mahi Drugs)
- Export destinations
- China, Indonesia, USA, Malaysia, Singapore, Spain, Brazil
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −37% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 83 | 85 | 79 | 78 | 81 | 63 | 68 |
| Expenses | 67 | 70 | 80 | 68 | 67 | 69 | 57 | 58 |
| Operating profit | 12 | 13 | 6 | 11 | 11 | 12 | 6 | 10 |
| Operating margin | 15.0% | 15.8% | 6.6% | 13.7% | 13.9% | 14.3% | 9.8% | 14.2% |
| Other income | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 9 | 9 | 3 | 7 | 7 | 7 | 3 | 5 |
| Tax rate | 29.8% | 27.6% | 19.8% | 31.0% | 29.4% | 27.8% | 29.6% | 38.6% |
| Net profit | 6 | 6 | 3 | 5 | 5 | 5 | 2 | 3 |
| EPS (₹ per share) | 19.88 | 20.61 | 8.86 | 17.07 | 16.47 | 17.89 | 7.38 | 10.72 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 317 | 300 | 333 | 301 |
| Expenses | 289 | 266 | 289 | 262 |
| Operating profit | 29 | 34 | 44 | 39 |
| Other income | 6 | 4 | 4 | 3 |
| Interest | 6 | 9 | 8 | 6 |
| Depreciation | 10 | 10 | 10 | 11 |
| Profit before tax | 18 | 19 | 30 | 25 |
| Net profit | 12 | 13 | 21 | 18 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 148 | 161 | 173 | 194 | 203 | 212 |
| Borrowings | 62 | 87 | 92 | 82 | 70 | 95 |
| Other liabilities | 99 | 86 | 80 | 80 | 118 | 94 |
| Total liabilities | 312 | 337 | 348 | 358 | 394 | 403 |
| Fixed assets | 99 | 140 | 138 | 150 | 226 | 190 |
| Capital work in progress | 21 | 1 | 6 | 0 | 9 | 1 |
| Investments | 23 | 23 | 23 | 23 | 0 | 23 |
| Other assets | 169 | 174 | 181 | 184 | 159 | 189 |
| Total assets | 312 | 337 | 348 | 358 | 394 | 403 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 22 | -15 | 5 | 15 | 28 | 38 |
| Cash from investing | -6 | -7 | -28 | -14 | -14 | -49 |
| Cash from financing | -8 | 15 | 23 | -1 | -14 | 11 |
| Net cash flow | 8 | -8 | -1 | 0 | 0 | 0 |
| Free cash flow | 14 | -30 | -24 | 1 | 14 | -11 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 42 | 36 | 53 | 60 | 71 | 66 |
| Inventory days | 154 | 143 | 154 | 168 | 131 | 180 |
| Days payable | 147 | 124 | 105 | 111 | 99 | 139 |
| Cash conversion cycle | 48 | 54 | 102 | 116 | 102 | 107 |
| Working capital days | 31 | 44 | 65 | 61 | 57 | 57 |
| Return on capital employed | 14.0% | 13.0% | 9.0% | 11.0% | 14.0% | 11.0% |
| Dividend payout | 3.0% | 2.0% | 3.0% | 3.0% | 2.0% | 3.0% |
What the price assumes
AttractiveTo justify its price of ₹1474, this stock must grow earnings at 20% every year for 7 years. Our analysis caps realistic growth at ~30%. At that growth it is worth ₹2503 — upside of 70%.
- Growth the price implies
- 19.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 32.9% a year
- net profit, FY23–FY26 · EPS 30.1%
- The gap
- -0.1 pp
- 70% downside if it only repeats history
Ownership
Who owns it
Promoters hold 72.10% as of Sept 2026; institutions added 0.00 pts since Jun 2026.
- Promoters 72.10%
- Foreign institutions 0.00%
- Domestic institutions 0.31%
- Public 27.58%
Who is on the register
Named in the Sep 2026 filing
Every holder of HALEOS LABS LIMITED above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 24.56% | unchanged | |
| 15.88% | unchanged | |
| 9.06% | unchanged | |
| 7.94% | unchanged | |
| 6.60% | unchanged | |
| 2.76% | unchanged | |
| 2.58% | unchanged | |
| 2.42% | unchanged | |
| 1.76% | unchanged | |
| 1.11% | unchanged | |
| 0.26% | unchanged | |
| 0.02% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for HALEOS LABS LIMITED
Free account: one company. Everything above stays public.
Write why you follow HALEOS LABS LIMITED and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse HALEOS LABS LIMITED
Guides on how to read this kind of business and the numbers that matter.